Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CRISPR breakthroughs are exciting—decoding the filings that fund them is not. Intellia Therapeutics’ reports weave gene-editing science, FDA guidance and collaboration accounting into 200-plus pages that overwhelm even seasoned analysts. Whether you’re hunting for "Intellia Therapeutics insider trading Form 4 transactions" before a clinical read-out or trying to spot fresh IP claims, the detail can feel impenetrable.
Stock Titan solves that problem. Our AI reads every "Intellia Therapeutics quarterly earnings report 10-Q filing" the moment it hits EDGAR, flags pivotal pipeline updates, and links R&D spend to trial timelines. Need "Intellia Therapeutics Form 4 insider transactions real-time"? We stream those alerts alongside plain-English context so you can judge sentiment swiftly. Our platform turns "Intellia Therapeutics SEC filings explained simply" from hope to reality by pairing side-by-side summaries with source paragraphs.
Use the page to:
- Compare cash runway and dilution scenarios with "Intellia Therapeutics earnings report filing analysis".
- Skim risk-factor changes in "Intellia Therapeutics annual report 10-K simplified" without scrolling endlessly.
- Track board pay packages via "Intellia Therapeutics proxy statement executive compensation" and assess alignment.
- Monitor "Intellia Therapeutics 8-K material events explained" for trial halts, collaborations, or FDA designations.
- Follow "Intellia Therapeutics executive stock transactions Form 4" to spot confidence shifts ahead of data.
- Accelerate due diligence by "understanding Intellia Therapeutics SEC documents with AI" instead of manual parsing.
Every filing—10-K, 10-Q, 8-K, Form 4, S-3, DEF 14A and more—updates in real time, wrapped in concise AI-powered insights. Spend minutes, not days, extracting the gene-editing intelligence that drives your next decision.
Intellia Therapeutics, Inc. (NTLA) – Form 4 insider transaction
EVP & Chief Technical Officer Eliana Clark reported the sale of 1,022 common shares on 01 July 2025 at a price of $9.82 per share (transaction code “S”). The shares had been purchased a day earlier under the company’s 2016 Employee Stock Purchase Plan and were therefore treated as non-derivative shares in Table I.
Following the disposition, Clark’s direct beneficial ownership stands at 95,369 shares. No derivative securities transactions were reported in Table II, and no Rule 10b5-1 trading plan box was checked, indicating the sale was executed outside of a pre-arranged trading program.
The filing represents a 1.1 % reduction in Clark’s directly held position (1,022 / 96,391 pre-sale) and is relatively small in dollar terms (~$10,000). No other insiders are included in this filing, and there is no indication of broader strategic implications for NTLA. Investors typically monitor insider activity for sentiment signals; however, a sale of this size by one executive is generally viewed as routine portfolio management rather than a material change in outlook.
Intellia Therapeutics (NTLA) has filed a Form 4 reporting that Vice President & Chief Accounting Officer Michael P. Dube sold 2,503 shares of common stock on 07/02/2025 at $9.95 per share. The filing states this was a mandatory sell-to-cover transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units (RSUs) on 07/01/2025, rather than a discretionary sale. After the transaction, Dube continues to hold 57,137 shares directly. No derivative positions were reported.
The dollar value of the sale (≈ $25 k) is immaterial relative to Intellia’s market capitalization and daily trading volume, and the officer retains a meaningful equity stake. As such, investors are likely to view the disclosure as routine housekeeping with neutral implications for the stock’s fundamental outlook.
Form 4 filing overview: On 07/02/2025, Chief Executive Officer Michael Heltzen reported an open-market purchase (transaction code “P”) of 1,040 shares of Exozymes Inc. (ticker EXOZ) common stock at a price of $10.22 per share. Following the transaction, Heltzen’s direct beneficial ownership increased to 10,628.8 shares. No derivative securities transactions were reported, and the filing was submitted individually (not jointly).
The purchase represents a modest addition to the CEO’s holdings and is the earliest reportable transaction for the period. Because the form lists no sales or derivative exercises, it signals a net increase in insider ownership.
Intellia Therapeutics, Inc. (NTLA) Form 4: Director Georgia Keresty reported new equity compensation dated 06/11/2025.
- 8,000 restricted stock units (RSUs) granted at $0 cost; each RSU converts into one common share.
- 11,450 stock options with a $8.37 exercise price; the option vests in full on the earlier of the first anniversary of grant or the next annual shareholder meeting and expires 06/10/2035.
- After the grant, Keresty directly owns 31,883 common shares.
No shares were sold or disposed of, and the filing reflects routine non-employee director compensation with negligible dilution and no impact on control or earnings.